Literature DB >> 9200098

Pentoxifylline inhibits overflow and reduces intestinal reperfusion injury.

C Savaş1, T Aras, M Cakmak, A Bilgehan, O Ataoğlu, N Türközkan, F Ozgüner, S Yücesan, H Dindar.   

Abstract

The aim of this study was to determine the effects of pentoxifylline (Ptx) in reperfusion injury of the small bowel as a leukocyte stabilizer, free radical scavenger, and microcirculatory regulator. Ninety-six male Sprague-Dawley rats were used to determine the biochemical, histopathologic and blood flow changes of the reperfused small intestines after 30 minutes of a warm ischemic insult. Animals were divided into six groups: Sham (S), sham plus Ptx (SP), ischemia (I), ischemia plus Ptx (IP), reperfusion (R), and reperfusion plus Ptx (RP). Pentoxifylline was administered intraperitoneally at a dose of 50 mg/kg 15 minutes before ischemia. The superior mesenteric artery (SMA) was occluded distal to the right colic artery and collateral arcades were ligated as described by Megison. Sixty of the 96 rats (n = 10) were used to determine histopathologic changes, malondialdehyde (MDA), and myeloperoxidase (MPO) levels in tissue. Mucosal lesions were graded on a scale from 0 to 5 as described by Chiu. MDA and MPO levels of the intestinal mucosa were assayed to reflect the free radical formation and neutrophil sequestration, respectively. Thirty-six rats (n = 6) were used to measure blood flow changes of the intestine using 133Xe clearance technique. All data were presented as the mean values plus or minus the standard error of the means (means +/- sem). Although in the R group, mucosal injury score, blood flow, MPO, and MDA levels were higher significantly from the other groups (P < .05), in the RP group blood flow, MPO, and MDA levels were significantly decreased to the basal values (P < .05). Mucosal injury score of the RP group were lower than the reperfusion group but higher than the normal (P < .05). The authors conclude that pentoxifylline pretreatment before reperfusion stabilizes blood flow, decreases MPO and MDA levels to the normal, and attenuates but not completely prevents mucosal damage.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9200098     DOI: 10.1016/s0022-3468(97)90648-5

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

1.  The effect of pentoxifylline on oxidative stress in CO2 pneumoperitoneum.

Authors:  Ayhan Dinckan; Emel Sahin; Mehmet Ogus; Kemal Emek; Saadet Gumuslu
Journal:  Surg Endosc       Date:  2008-03-18       Impact factor: 4.584

2.  Alpha-tocopherol ameliorates oxidative renal insult associated with spinal cord reperfusion injury.

Authors:  Mohamed D Morsy; Salah O Bashir
Journal:  J Physiol Biochem       Date:  2013-01-24       Impact factor: 4.158

3.  Pentoxifylline improves blood flow to both testes in testicular torsion.

Authors:  Cağri Savaş; Hüseyin Dindar; Tülin Aras; Selçuk Yücesan
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

4.  Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases.

Authors:  Ming Zhang; Yan-Jun Xu; Shushma A Mengi; Amarjit S Arneja; Naranjan S Dhalla
Journal:  Exp Clin Cardiol       Date:  2004

5.  Short-term intestinal ischemia-reperfusion alters intestinal motility that can be preserved by xanthine oxidase inhibition.

Authors:  Gülce Hakgüder; Feza M Akgür; Oğuz Ateş; Mustafa Olguner; Tanju Aktuğ; Erdener Ozer
Journal:  Dig Dis Sci       Date:  2002-06       Impact factor: 3.199

6.  Protective effects of pentoxifylline in small intestine after ischemia-reperfusion.

Authors:  Seracettin Eğin; Mehmet İlhan; Süleyman Bademler; Berk Gökçek; Semih Hot; Hakan Ekmekçi; Özlem Balcı Ekmekçi; Gamze Tanrıverdi; Fatma Kaya Dağıstanlı; Gülçin Kamalı; Sedat Kamalı; Recep Güloğlu
Journal:  J Int Med Res       Date:  2018-07-20       Impact factor: 1.671

7.  Sesamin ameliorates mucosal tissue injury of mesenteric ischemia and reperfusion in an experimental rat model.

Authors:  Mustafa B Sayhan; Serhat Oguz; Ömer Salt; Nuray Can; Taner Ozgurtas; Tulın D Yalta
Journal:  Arch Med Sci       Date:  2018-12-10       Impact factor: 3.318

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.